

# SHAKTI, CRAMS, and India's Leap into High Value Biopharma

India is a key global pharmaceutical supplier, accounting for **~20% of generic drug volumes** and **~60% of vaccine supply**. Ranked **third globally by production volume**, this scale provides a robust base to move into higher-value biopharma segments.

**Biopharma SHAKTI** (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation) is the centrepiece of Budget 2026 for health—**₹10,000 crore over five years** to build an end to end ecosystem for biologics and biosimilars.



## Key focus areas under SHAKTI:

- A national **push to scale complex biomanufacturing** (vaccines, therapeutic proteins, potentially cell/gene therapies) and reduce import dependence in high value biologics.
- A network of **~1,000 accredited clinical trial sites**—expanding beyond the top metros—to enable globally credible, faster biologics/biosimilar development.
- **CDSCO (Central Drugs Standard Control Organisation) to be strengthened** with a dedicated scientific review cadre and time bound approvals aligned to global standards.
- **Three new NIPERs (National Institute of Pharmaceutical Education and Research) + upgrade of seven existing institutes** to build specialised skills in biologics manufacturing, regulatory science and clinical research.
- SHAKTI sits alongside **the government's broader innovation and digital health agenda** (ABDM, research allocations), reinforcing data driven trials and tech enabled delivery.



## Beyond SHAKTI: Budget 2026 health sector reinforcements

- **Health allocation crosses ₹1 lakh crore** for the first time, representing a nearly 10% increase over the previous year, with higher spending earmarked for hospitals, medicines, public health programmes and healthcare infrastructure.
- Affordability boost: **Basic customs duty waived on 17 critical cancer drugs**; duty free imports extended for medicines & specialised nutrition used in treating seven rare diseases—direct relief for patients needing advanced therapies.
- **3 new All India Institutes of Ayurveda**, upgrades to AYUSH pharmacies/drug testing labs, and five regional medical hubs with AYUSH, diagnostics and rehab to lift wellness and medical value travel.
- Plan for NIMHANS 2.0 (north India) and upgrades to national mental health institutes—broadening tertiary care beyond metros.



**CRAMS/CDMO** (Contract Research & Manufacturing Services, often called CRAMS/CDMO) remains a well-established competitive advantage for India in healthcare manufacturing— and Budget 2026 amplifies this advantage.


- **India's CRAMS market is forecast to add ~US\$17.1 bn between 2024–2029 at ~11.8% CAGR**, driven by outsourcing across discovery, development, analytics and commercial manufacturing.
- The global CRAMS industry is projected to grow ~10–11% CAGR through 2030—biologics outsourcing, analytical/QC and integrated CDMO models are the fastest growing pockets.
- Why India leads: the **largest number of US FDA-approved manufacturing plants outside the US**, a major trust differentiator as well as demonstrated strength in complex generics, biosimilars, and high volume manufacturing makes India a preferred outsourcing destination.

As India's healthcare transformation accelerates—from biopharma scale up to CRAMS expansion and the broader wellness boom—the shift reflects a long term megatrend rather than a cyclical phase. Within this landscape, the **Bajaj Finserv Healthcare Fund** seeks to provide diversified exposure to the healthcare segment through a research-driven investment approach.

#### COMPOSITION BY INDUSTRY (%)



#### Market Cap Allocation



**Sources:** IBEF, PIB, KPMG, Internal Analysis | Data as on 1<sup>st</sup> February, 2026.

Past performance may or may not be sustained in future.

This document should not be treated as endorsement of the views/opinions or as an investment advice. This document should not be construed as a research report or a recommendation to buy or sell any security. This document alone is not sufficient and should not be used for the development or implementation of an investment strategy. The recipient should note and understand that the information provided above may not contain all the material aspects relevant for making an investment decision. The decision of the Investment Manager may not always be profitable; as such decisions are based on the prevailing market conditions and the understanding of the Investment Manager. Actual market movements may vary from the anticipated trends. Neither Bajaj Finserv Mutual Fund / Bajaj Finserv Mutual Fund Trustee Limited / Bajaj Finserv Asset Management Limited nor its Directors or employees shall be liable for any damages whether direct or indirect, incidental, punitive special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Investors are advised to consult their own investment advisor before making any investment decision in light of their risk appetite, investment goals and horizon. This information is subject to change without any prior notice.

#### Bajaj Finserv Healthcare Fund


An open ended equity scheme following pharma, healthcare and allied theme

This product is suitable for investors who are seeking\*:


- wealth creation over long term
- to invest predominantly in equity and equity related instruments of pharma, healthcare and allied companies.

\*Investors should consult their financial advisers if in doubt about whether the product is suitable for them

#### SCHEME RISK-O-METER



#### BENCHMARK RISK-O-METER



**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.**